home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0117.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
2KB
|
32 lines
Document 0117
DOCN M94A0117
TI Teniposide: overview of its therapeutic potential in adult cancers.
DT 9412
AU Muggia FM; University of Southern California, Norris Cancer Center, Los;
Angeles 90033.
SO Cancer Chemother Pharmacol. 1994;34 Suppl:S127-33. Unique Identifier :
AIDSLINE MED/94349497
AB Teniposide was introduced into clinical trials prior to etoposide, but
its role was not defined because interest shifted early on to etoposide.
However, long-term encouraging results obtained in acute leukemia
treated with teniposide have rekindled interest in this compound. In
addition to pharmacokinetic differences, teniposide has greater CNS
penetrance and is more lipophilic. Its greater potency is related to
enhanced intracellular uptake. Although its antitumor spectrum of
activity appears to be very similar to that of etoposide, a search for
some differences might prove instructive.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Brain
Neoplasms/DRUG THERAPY Carcinoma, Non-Small-Cell Lung/DRUG THERAPY
Carcinoma, Small Cell/DRUG THERAPY Clinical Trials Clinical Trials,
Phase I Comparative Study Etoposide/TOXICITY/THERAPEUTIC USE Female
Genital Neoplasms, Female/DRUG THERAPY Hodgkin's Disease/DRUG THERAPY
Human Leukemia/*DRUG THERAPY Lung Neoplasms/DRUG THERAPY
Lymphoma/*DRUG THERAPY Lymphoma, Non-Hodgkin's/DRUG THERAPY
Neoplasms/*DRUG THERAPY Sarcoma, Kaposi's/DRUG THERAPY/ETIOLOGY
Teniposide/*TOXICITY/*THERAPEUTIC USE JOURNAL ARTICLE REVIEW REVIEW,
TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).